Candel Therapeutics (CADL) Stock Analysis

What Candel Therapeutics does

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.

Key metrics

ETFs linked to CADL

Broad-market and Healthcare sector ETFs an investor holding Candel Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CADL fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Candel Therapeutics?

Candel Therapeutics trades under the ticker CADL on NASDAQ.

Which exchange is CADL listed on?

CADL is listed on NASDAQ.

What sector does Candel Therapeutics operate in?

Candel Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CADL in a portfolio?

PortView shows CADL's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.